| Dr James L Hutchison, MD | |
|
525 Branson Landing Blvd Ste 100, Branson, MO 65616-2152 | |
| (417) 348-8646 | |
| (417) 335-7529 |
| Full Name | Dr James L Hutchison |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 28 Years |
| Location | 525 Branson Landing Blvd Ste 100, Branson, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275546012 | NPI | - | NPPES |
| 209801612 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 110504 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cox Medical Center Branson | Branson, MO | Hospital |
| Cox Medical Centers | Springfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cox-monett Hospital Inc | 0345236667 | 50 |
| Lester E Cox Medical Centers | 1254248917 | 262 |
| Skaggs Community Hospital Association | 5092624320 | 133 |
News Archive
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.
Although the Americans with Disabilities Act (ADA) has helped increase awareness of barriers faced by people with disabilities, and advances in science and engineering have led to better assistive technologies that make it easier for individuals to lead productive, independent lives, outdated regulations too often impede access to health care coverage and assistive devices for many who need them, says a new report by the Institute of Medicine.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.
› Verified 7 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538334396 PECOS PAC ID: 1254248917 Enrollment ID: O20050624000293 |
News Archive
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.
Although the Americans with Disabilities Act (ADA) has helped increase awareness of barriers faced by people with disabilities, and advances in science and engineering have led to better assistive technologies that make it easier for individuals to lead productive, independent lives, outdated regulations too often impede access to health care coverage and assistive devices for many who need them, says a new report by the Institute of Medicine.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.
› Verified 7 days ago
| Entity Name | Skaggs Community Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346602646 PECOS PAC ID: 5092624320 Enrollment ID: O20160517000289 |
News Archive
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.
Although the Americans with Disabilities Act (ADA) has helped increase awareness of barriers faced by people with disabilities, and advances in science and engineering have led to better assistive technologies that make it easier for individuals to lead productive, independent lives, outdated regulations too often impede access to health care coverage and assistive devices for many who need them, says a new report by the Institute of Medicine.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.
› Verified 7 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669923884 PECOS PAC ID: 1254248917 Enrollment ID: O20161206000652 |
News Archive
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.
Although the Americans with Disabilities Act (ADA) has helped increase awareness of barriers faced by people with disabilities, and advances in science and engineering have led to better assistive technologies that make it easier for individuals to lead productive, independent lives, outdated regulations too often impede access to health care coverage and assistive devices for many who need them, says a new report by the Institute of Medicine.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.
› Verified 7 days ago
| Entity Name | Cox-monett Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205387289 PECOS PAC ID: 0345236667 Enrollment ID: O20161213002029 |
News Archive
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.
Although the Americans with Disabilities Act (ADA) has helped increase awareness of barriers faced by people with disabilities, and advances in science and engineering have led to better assistive technologies that make it easier for individuals to lead productive, independent lives, outdated regulations too often impede access to health care coverage and assistive devices for many who need them, says a new report by the Institute of Medicine.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.
› Verified 7 days ago
| Entity Name | Skaggs Community Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255870853 PECOS PAC ID: 5092624320 Enrollment ID: O20170310001975 |
News Archive
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.
Although the Americans with Disabilities Act (ADA) has helped increase awareness of barriers faced by people with disabilities, and advances in science and engineering have led to better assistive technologies that make it easier for individuals to lead productive, independent lives, outdated regulations too often impede access to health care coverage and assistive devices for many who need them, says a new report by the Institute of Medicine.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James L Hutchison, MD Po Box 802843, Kansas City, MO 64180-2843 Ph: (417) 730-6430 | Dr James L Hutchison, MD 525 Branson Landing Blvd Ste 100, Branson, MO 65616-2152 Ph: (417) 348-8646 |
News Archive
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.
Although the Americans with Disabilities Act (ADA) has helped increase awareness of barriers faced by people with disabilities, and advances in science and engineering have led to better assistive technologies that make it easier for individuals to lead productive, independent lives, outdated regulations too often impede access to health care coverage and assistive devices for many who need them, says a new report by the Institute of Medicine.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.
› Verified 7 days ago
Saima Rehman Qureshi, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2715 W 76 Country Blvd Ste 103, Branson, MO 65616 Phone: 417-317-5318 | |
Roy Jack Gillispie, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 5136 Hwy 265, Branson, MO 65616 Phone: 417-338-0960 Fax: 417-338-0968 | |
Alok Shukla, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1140 W Highway 76, Branson, MO 65616 Phone: 417-317-5318 Fax: 417-763-3370 | |
Jeremy D Mabe, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1150 State Highway 248, Ste. 202, Branson, MO 65616 Phone: 417-348-8964 Fax: 417-336-0275 | |
Dr. Cody Stark Rogers, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 Branson Landing Blvd, Branson, MO 65616 Phone: 417-335-7128 Fax: 417-348-8007 | |
Sabera Shabnam, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 Branson Landing Blvd Ste 201a, Branson, MO 65616 Phone: 417-335-7128 Fax: 417-348-8007 | |
Dr. Lisa Requena, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 Branson Landing Blvd, Branson, MO 65616 Phone: 417-348-8646 Fax: 417-335-7529 |